|
|
|
市场调查报告书
全球癌症治疗和生物疗法市场:第4版
The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies), 4th Edition
|
全球癌症治疗和生物疗法市场:第4版 是由出版商Kalorama Information在2012年01月所出版的。
这份英文市场调查报告书包含245 Pages 价格从美金3500起跳。
本报告以癌症治疗为焦点，汇整现在上市的治疗药物及开发后期阶段的药物概要及市场收益，各产品的销售额等数据汇整，参与企业简介，为您概述为以下内容。
第1卷 摘要整理
第2章 简介
- 癌症是什么
- 癌症治疗市场历史和成长
- 产业结构
- 人口统计
- 寿命和癌症
- 癌症详细内容
第3章 化疗
第4章 荷尔蒙疗法
- 概要
- 产品概要与案例
- 皮质类固醇
- 荷尔蒙作用药与拮抗剂
- 芳香酶抑制剂
- 雌激素受体调整
- 市场规模与成长
- 竞争分析
第5章 生物疗法
- 概要
- 产品概要与案例
- 单株抗体
- 白细胞介素/干扰素
- 酪氨酸激酶抑制剂
- 其他生物疗法
- 放射免疫疗法
- 市场规模与成长
- 竞争分析
第6章 全球癌症治疗:整体市场规模与预测
第7章 影响癌症市场的问题与趋势
- 简介
- 保险和报销问题
- 癌症治疗成本
- 个体化医疗
- 癌症标靶治疗
- 医药基因学
- 合作，收购，授权契约
- 病人报告结果
- 酒精的影响
- 健康的生活方式可以预防癌症
- 癌症趋势
- 行销和销售趋势
- 各地区趋势
- 成人临床实验参与计划
- 开发后期药物趋势
- 最近的NDA活动
- 新核准
第8章 企业简介
- 简介
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly & Company
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis AG
- Pfizer, Inc.
- Roche
- Sanofi
第9章 竞争企业名录
图表
Abstract
This Kalorama Information report - The World Market for Cancer Therapeutics
and Biotherapeutics, 4th Edition - focuses on several segments for cancer
treatment including:
- Chemotherapy, including -subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each
- Hormone Therapy: -Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS-Brands such as Arimidex, Casodex, Zoladex, Femara and Lupron with Market Share for each.
- Immunotherapy and Biotherapy, including: -Monoclonal antibodies, interleukins/interferons, vaccines and other biotherapy-Brands such as Rituxan, Herceptin, Gleevec, Evastin and Erbitux
One of the most promising new approaches in modern cancer treatment is
immunotherapy or biotherapy, the development of methods to augment and enhance
the body' s natural tendency to defend itself against malignant tumors without
damaging healthy tissue. The report devotes particular attention to these new
therapies.
This report, Kalorama' s fourth complete research effort into the oncology
treatments market in the past ten years, provides market size information for
the various types of cancers including the following:
- Bladder
- Breast
- Cervical
- Colorectal
- Esophageal
- Head/Neck
- Kidney
- Leukemia
- Liver
- Lung
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian
- Pancreatic
- Prostate
- Stomach
The report covers both currently marketed and late stage development cancer
products. Revenues for each current market segment were generated using dollar
and unit sales for each product.
The report includes statistical information for cancers by type worldwide,
with special emphasis on the U.S. market. Specifically, cancers where there
are current products available or are in development and/or have significant
incidence/mortality rates are profiled. The market segments provide an
overview, description of products on the market, leading product sales, market
estimates and forecasts, and competitive analysis of leading providers. The
report also includes a list of products in development and current issues and
trends affecting the industry.
The information for this report was gathered using both primary and secondary
research including comprehensive research of secondary sources such as company
literature, databases, investment reports, and medical and business journals.
Telephone interviews and email correspondence were the primary method of
gathering information. For the purpose of this study Kalorama Information
conducted interviews with key industry officials, consultants, health care
providers, and government personnel. These sources were the primary basis in
gathering information specifically relating to revenue and market share data
presented in this report. Specific interviews with pharmaceutical company
representatives included marketing directors, division managers, and product
representatives.
As part of its coverage, the report looks at the following trends:
- Insurance and Reimbursement Issues
- Cancer Drug Costs
- Personalized Medicine
- Targeted Cancer Therapy
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Patient-Reported Outcomes
- Alcohol' s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Obesity in the U.S.
- Outlook for a Healthier U.S. Population
- Cancer Trends
- Marketing and Distribution Trends
- Geographical Trends (US, Europe, Japan)
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
All market data pertains to the world market at the manufacturers' level. The
base year for data was 2010. Historical data was provided for the years 2005
through 2009, with forecast data provided for 2011 through 2015. Compound
annual growth rates (CAGRs) are provided for the 2005-2010, 2010-2015 and
2005-2015 periods for each industry segment covered. Competitive analysis is
provided for the year 2010. The forecasted market analysis for 2010-2015 was
based on probability of approval and sales of products in late stage
development, competitive trends, product marketing, and demographic trends.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- What is Cancer
- Biochemistry of Cancer Cells
- Carcinogen Metabolism
- Causes of Cancer Growth
- Environmental Factors, DNA, RNA
- Cellular Oncogenes
- Tumor Suppressor Genes
- History and Growth of the Cancer Treatment Market
- Industry Structure
- Product Segments and Technology
- Chemotherapy: At a Glance
- Hormone Therapy: At A Glance
- Biotherapy: At A Glance
- Radiation Therapy: At a Glance
- Demographics and Statistics
- Global Cancer Statistics
- Demographics
- Aging Population
- Life Expectancy and Cancer
- Life Expectancy
- Birth Rates
- Description of Cancers
- Bladder Cancer
- Brain Cancer
- Glioblastoma
- Neuroblastoma
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Head and Neck
- Kidney
- Leukemia
- Liver
- Lung Cancer
- Lymphoma
- Melanoma
- Multiple Myeloma
- Ovarian Cancer
- Pancreas
- Prostate Cancer
- Stomach Cancer
CHAPTER THREE: CHEMOTHERAPY
- Overview
- Product Descriptions and Examples
- Alkylating Agents
- Antimetabolites
- Cytotoxic Agents
- Plant Derivatives
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- European Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
CHAPTER FOUR: HORMONE THERAPY
- Overview
- Product Descriptions and Examples
- Corticosteroids
- Hormone Agonists and Antagonists
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
CHAPTER FIVE: BIOTHERAPEUTICS
- Overview
- Product Descriptions and Examples
- Monoclonal Antibodie
- Interleukins/Interferons
- Tyrisoine Kinase Inhibitors
- Other Biotherapeutics
- Radioimmunotherapy
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
- Overview
- Total Market Size and Forecast
- Geographical Market Distribution
- Competitive Landscape
CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
- Introduction
- Insurance and Reimbursement Issues
- Cancer Drug Costs
- Personalized Medicine
- Targeted Cancer Therapy
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Patient-Reported Outcomes
- Alcohol' s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Obesity in the U.S.
- U.S. Obesity Rates Differ Among Ethnic Groups
- Outlook for a Healthier U.S. Population
- Cancer Trends
- Marketing and Distribution Trends
- Geographical Trends
- United States
- Europe
- Japan
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
- Significant Developments
- Alpharadin
- Afatinib
- Axitinib
- Bosutinib
- Brentuximab
- Carfilzomib
- Crizotinib
- Erwinaze
- Exelbine
- Motesanib
- Omnitarg
- Regorafenib
- Ridaforolimus
- Zaltrap
- Recent NDA Activity
- New Approvals
CHAPTER EIGHT: CORPORATE PROFILES
- Introduction
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly & Company
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis AG
- Pfizer, Inc.
- Roche
- Sanofi
APPENDIX: MAJOR COMPETITOR DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: World Cancer Market
- Table 1-2: Market by Product Type (Chemotherapy, Hormone Therapy,
Biotherapeutics), 2005-2015
- Figure 1-1: World Cancer Market, Market by Product Type (Chemotherapy,
Hormone Therapy, Biotherapeutics), 2005-2015
- Figure 1-2: World Cancer Market, Market by Product Type and Percent Market
Share, 2010
CHAPTER TWO: INTRODUCTION
- Table 2-1: Viruses Associated with Cancer in Humans
- Figure 2-1: Approved Cancer Therapies in the United States by Primary
Indication
- Table 2-2: World Cancer Incidence by Selected Types of Cancer, 2010 and
2020, (Lung,Breast, Colon/ Rectum, Stomach, Liver, Prostate, Cervical,
Ovarian, Lymphoma, Pancreatic, Melanoma)
- Figure 2-2: Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2010 and 2020
- Table 2-3: Total Cancer Incidence by Sex and Country(Canada, China,
France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom,
United States), 2010 Estimates
- Figure 2-3: Total Cancer Incidence by Sex and Country(Canada, China,
France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom,
United States), 2010 Estimates
- Table 2-4: World Population by Selected Geographical Region(Africa, Asia,
Europe, North America, Oceania, South America, World), 2010 - 2050
- Figure 2-4: World Population by Selected Geographical Region(Africa, Asia,
Europe, North America, Oceania, South America, World), 2010-2050
- Table 2-5: Percent Population Over 65 by Year and Region, 2010-2050
- Figure 2-5: Estimated World Population by Age, 2010 and 2050
- Table 2-6: Average Life Expectancy in Years by Country 1980, 2004 and 2009
- Figure 2-6: Average Life Expectancy in Years by Country 1980 and 2009
- Figure 2-7: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2006
- Figure 2-8: United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2006
- Table 2-7: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
- Figure 2-9: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
- Table 2-9: Types of Leukemia
- Table 2-9: Types of Primary Lung Cancer
- Table 2-10: Classification of Non-Hodgkin' s Lymphomas
- Table 2-11: Malignant Conditions of the Skin
CHAPTER THREE: CHEMOTHERAPY
- Table 3-1: Leading Products, 2010
- Table 3-2: World Chemotherapy Market, 2005-2015
- Figure 3-1: World Chemotherapy Market, 2005-2015
- Table 3-3: World Chemotherapy Market, Sales by Drug Classification,
(Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives) 2010
- Figure 3-2: World Chemotherapy Market by Drug Classification, (Alkylating
Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives)
- Table 3-4: World Chemotherapy Market, Sales by Drug Classification
(Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives),
Estimated 2010)
- Figure 3-3: World Chemotherapy Market by Drug Classification (Alkylating
Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives), Estimated 2015
- Figure 3-4: World Chemotherapy Current Market by Region (US, EU, Japan,
ROW)
- Figure 3-5: World Chemotherapy Market by Region 2015 (US, EU, Japan, ROW)
- Table 3-5: World Chemotherapy Market Type by Cancer Type (Lung, Breast,
Colon, Brain, Ovarian, Other Total)
- Figure 3-6: World Chemotherapy Market by Cancer Type (Lung, Breast, Colon,
Brain, Ovarian, Other Total)
- Table 3-6: World Chemotherapy Market, Leading Suppliers Shares by Market
Revenues, 2010
- Figure 3-7: World Chemotherapy Market, Leading Suppliers Market Share, 2010
CHAPTER FOUR: HORMONE THERAPY
- Table 4-1: Leading Products, 2010
- Table 4-2: World Hormone Therapy Market, 2005-2015
- Figure 4-1: World Hormone Therapy Market, 2005-2015
- Table 4-3: World Hormone Therapy Market, Sales by Drug Classification (
Corticosteroids, Hormone agonists/ Antagonists, Aromatase Inhibitors, SERMs),
2010
- Figure 4-2: World Hormone Therapy Market, Market by Drug Classification
(Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors, SERMs)
and Percent Market Share, 2010
- Table 4-4: World Hormone Therapy Market, Sales by Drug Classification
(Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors ,
SERMs), Estimated 2015
- Figure 4-3: World Hormone Therapy Market, Market by Drug Classification
(Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors, SERMs)
and Percent Market Share, 2015
- Figure 4-4: World Hormone Therapy Current Market by Region (US, EU, Japan,
ROW)
- Figure 4-5: World Hormone Therapy Market by Region 2015 (US, EU, Japan,
ROW)
- Table 4-5: World Hormone Therapy Market by Cancer Type (Breast, Prostate,
Other)
- Figure 4-6: World Hormone Therapy Market by Cancer Type (Breast, Prostate,
Other)
- Table 4-6: World Hormone Therapy Market, Leading Suppliers Shares by
Market Revenues, 2010
- Figure 4-7: World Hormone Therapy Market, Leading Suppliers Market Share,
2010
CHAPTER FIVE: BIOTHERAPEUTICS
- Table 5-1: Leading Biopharmaceutical Cancer Treatment Products (Brand
Name, Generic Name, Manufacturer/ Marketer, Common Uses, Annual Sales ), 2010
- Table 5-2: World Cancer Biotherapeutics Market, 2005-2015
- Figure 5-1: World Cancer Biotherapeutics Market, 2005-2015
- Table 5-3: World Biotherapeutics Market, Sales by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics), 2010
- Figure 5-2: World Biotherapeutics Market by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics)
- Table 5-4: World Biotherapeutics Market, Sales by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics), Estimated 2015
- Figure 5-3: World Biotherapeutics Market by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics), Estimated 2015
- Figure 5-4: World Cancer Biotherapeutics Market by Region (US, EU, Japan,
ROW)
- Figure 5-5: World Cancer Biotherapeutics Market by Region (US, EU, Japan,
ROW) , Estimated 2015
- Table 5-5: World Cancer Biotherapeutics Market by Cancer Type (Colon,
Breast, Lymphoma, Leukemia, Others)
- Figure 5-6: World Cancer Biotherapeutics Market by Cancer Type(Colon,
Breast, Lymphoma, Leukemia, Others)
- Table 5-6: World Biotherapeutics Market, Leading Suppliers Shares by
Market Revenues, 2010
- Figure 5-7: World Cancer Biotherapeutics Market, Leading Suppliers Market
Share, 2010
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
- Table 6-1: World Cancer Market, Market by Product Type, 2005-2015
- Figure 6-1: World Cancer Market, Market by Product Type Revenues, 2005-2015
- Figure 6-2: World Cancer Market, Market by Product Type and Percent Market
Share, 2010
- Figure 6-3: World Cancer Market, Market by Product Type and Percent Market
Share, 2015
- Table 6-2: World Cancer Market, Leading Suppliers' Shares by Market
Revenues, 2010
- Figure 6-5: World Cancer Market, Leading Suppliers' Market Share, 2010
CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
- Table 7-1: Obesity Rates by U.S. State, 2009
- Table 7-2: Select Products in Development by Development Phase
- Figure 7-1: Late Stage Cancer Compounds in Development for Major
Indications, Distribution Estimates
- Table 7-3: Recent NDA Activity: January 2011-July 2011
- Table 7-4: Select New Approvals (NCE, Indications, Dosage, Formulations)
,2010-11
CHAPTER EIGHT: CORPORATE PROFILES
- Figure 8-1: Late stage Cancer Therapies in Development for Leading
Companies
酪胺酸激酶抑制剂在癌治疗药的销售额扩大市占率
2011年10月24日
Global Information, Inc.已开始销售Kalorama Information所发行的报告书「The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies), 4th Edition (全球癌症治疗和生物疗法市场:第4版)」
名叫Gleevac和Nexavar的酪胺酸激酶抑制剂，是在癌治疗市场最迅速成长的领域，牵引许多制药公司的成果。医疗市场的调查公司Kalorama Information推定，2010年全球癌治疗市场为544亿美元规模。
Kalorama Information的Bruce Carlson述说：「过去5年癌的生物疗法急剧成长，从荷尔蒙及化学疗法的销售额中夺走市占率。」。「而且，在此领域，酪胺酸激酶抑制剂的有效性已很明显，销售额迅速成长。」
受容体酪胺酸激酶抑制剂的突然变异，已成为细胞增殖及人类生病的原因。Iressa和Tarceva、Tykerb、Sprycel、Tasigna、Sutent 及此领域称作Votrient的最新治疗药，阻碍了受容体的功能，抑制癌的异常细胞增殖。聚焦于此最新治疗法研发出的治疗药之销售额，将继续平稳。Kalorama Information分析，过去5年酪胺酸激酶抑制剂比其他任何的癌治疗药更迅速以约26.7％成长。
本报告书中叙述，癌发生率上升，尤其是50岁以上者增加，对癌治疗的所有侧面可能有重大影响。然对许多的癌来说，依然存在有效果治疗之重大未被满足的需求。例如，肺癌为其一例，患者生存期间从发现到死亡不满5年。本报告书亦介绍正在开发的新治疗法。
|
 |
